» Articles » PMID: 20370816

Seizures and Paroxysmal Events: Symptoms Pointing to the Diagnosis of Pyridoxine-dependent Epilepsy and Pyridoxine Phosphate Oxidase Deficiency

Overview
Date 2010 Apr 8
PMID 20370816
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: We report on seizures, paroxysmal events, and electroencephalogram (EEG) findings in four female infants with pyridoxine-dependent epilepsy (PDE) and in one female with pyridoxine phosphate oxidase deficiency (PNPO).

Method: Videos and EEGs were analysed and compared with videos of seizures and paroxysmal events archived from 140 neonates. PDE and PNPO were proven by complete control of seizures once pyridoxine or pyridoxal 5'-phosphate was administered and by recurrence when withdrawn. Mutations in the antiquitin gene were found in three patients and in the PNPO gene in one child.

Results: Seizures began within 48 hours after birth in four newborns and at age 3 weeks in one. Frequent multifocal and generalized myoclonic jerks, often intermixed with tonic symptoms, abnormal eye movement, grimacing, or irritability, were observed in all infants with PDE and PNPO, but rarely in the other archived videos of neonates. EEGs were inconstant and frequently no discernable ictal changes were recorded during the seizures and the paroxysmal events. In addition, interictal EEGs were inconclusive, with normal and abnormal recordings. In older children tonic-clonic seizures, abnormal behaviour, inconsolable crying, frightened facial expression, sleep disturbance, loss of consciousness, paraesthesia, or intermittent visual symptoms were described during controlled and uncontrolled withdrawal or insufficient dosage.

Interpretation: PDE or PNPO should be considered in infants with prolonged episodes of mixed multifocal myoclonic tonic symptoms, notably when associated with grimacing and abnormal eye movements.

Citing Articles

Metabolic pathways and genes involved in treatable and non-treatable metabolic epilepsies. A comprehensive review and metabolic pathway analysis.

Sesse A, Ladias P, Kostoulas C, Chatzistefanidis D, Georgiou I, Markoula S Metab Brain Dis. 2025; 40(3):152.

PMID: 40085371 DOI: 10.1007/s11011-025-01562-5.


Utility and limitations of EEG in the diagnosis and management of -related pyridoxine-dependent epilepsy. A retrospective observational study.

Arntsen V, Jamali A, Sikiric A, Kristensen E, Tangeraas T, Kupliauskiene G Front Neurol. 2024; 15:1355861.

PMID: 38419708 PMC: 10899485. DOI: 10.3389/fneur.2024.1355861.


Comparing the Efficacy and Safety of Levetiracetam Versus Phenytoin for Treating the Acute Phase of Neonatal Seizures.

Mohammadi M, Kadivar M, Sangsari R, Mirnia K, Saeedi M, Adhami P Iran J Child Neurol. 2023; 17(1):65-71.

PMID: 36721831 PMC: 9881830. DOI: 10.22037/ijcn.v17i1.36008.


Pyridoxine Trial in Early Infantile Epileptic Encephalopathy: Never Forget!.

Sharawat I, Suthar R, Saini A, Sankhyan N Ann Indian Acad Neurol. 2021; 23(5):727-729.

PMID: 33623288 PMC: 7887496. DOI: 10.4103/aian.AIAN_204_19.


Inborn errors in the vitamin B6 salvage enzymes associated with neonatal epileptic encephalopathy and other pathologies.

Ghatge M, Al Mughram M, Omar A, Safo M Biochimie. 2021; 183:18-29.

PMID: 33421502 PMC: 11273822. DOI: 10.1016/j.biochi.2020.12.025.